Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

Todd Neale

July 19, 2022

News Daily News

Cardiometabolic Diseases Contribute to Bulk of COVID-19 Hospitalizations

Todd Neale

March 04, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

Michael O'Riordan

January 25, 2021

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

Advertisement

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

CVD, Diabetes Spike in Acute Phase of COVID-19

Cardiometabolic Diseases Contribute to Bulk of COVID-19 Hospitalizations

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Vitamin D, Calcium, Other Vitamins, and Supplements Do Not Prevent CVD

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content